Prescription Drug News and Research

RSS

New comprehensive trademark search capabilities available for pharmaceutical industry

CT Corsearch, part of CT, a Wolters Kluwer business and the premier provider of clearance and protection solutions for trademark and brand professionals, today announced the availability of its new comprehensive trademark search capabilities designed specifically for the specialized needs of the pharmaceutical industry.

16 Mar 2010

Metabolic drugs top the list of prescription drug expenses for elderly Medicare beneficiaries

Purchases of cholesterol and diabetes prescription drugs by elderly Medicare beneficiaries reached nearly $19 billion in 2007 - about one-fourth of the approximately $82 billion spent for medications for the elderly, according to the latest AHRQ News and Numbers.

16 Mar 2010

President delivers emotional speech, pushes for reform in Ohio

The Associated Press: "With a fresh sense of urgency, President Barack Obama sought to reassure seniors Monday about health care legislation approaching a final vote in Congress, pledging it would make preventive care cost-free and close a gap in Medicare prescription drug coverage. 'This proposal adds almost a decade of solvency to Medicare,' Obama said in a visit to a senior center."

16 Mar 2010

BioSante Pharmaceuticals receives receipt of Orphan Drug designation for GVAX Pancreas Vaccine

BioSante Pharmaceuticals, Inc. today announced BioSante’s receipt of Orphan Drug designation from the FDA’s Office of Orphan Products Development for GVAX Pancreas Vaccine in the treatment of pancreatic cancer.

15 Mar 2010

A.P. Pharma reports net loss of $1.9M for fourth-quarter of 2009

A.P. Pharma, Inc., a specialty pharmaceutical company, today reported financial results for its fourth quarter and full year ended December 31, 2009.

15 Mar 2010

Parliamentarian ruling complicates Democrats' plans

The Democrats' plan for passing the health overhaul has been waylaid by the Senate parliamentarian, who ruled President Obama must first sign into law the Senate-passed health bill before the senators could consider separate legislation that would alter it on behalf of House members, The Hill reports.

15 Mar 2010

Arena Pharmaceuticals reports lower net loss allocable to common stockholders in fourth-quarter 2009

Arena Pharmaceuticals, Inc. today reported financial results for the fourth quarter and full year ended December 31, 2009.

12 Mar 2010

Does Medicare 'doughnut hole' spur increase in foreign drug imports?

Medill Reports: "Unless federal legislation closes the Medicare coverage gap colloquially known as the 'doughnut hole,' seniors may opt for online drug imports to alleviate steep prescription costs. ... 'As seniors start falling into the doughnut hole, they are going online to find deals on prescription drugs, whether they're based in the U.S. or in other countries,' said Gabriel Levitt, vice president of PharmacyChecker.com LLC, a leader in the evaluation of online and mail-order pharmacies in both the U.S. and abroad.

12 Mar 2010

Congress, Obama continue health reform push

"Health care reform takes center stage Thursday as President Obama and top congressional Democrats work behind closed doors to nail down a final agreement," CNN reports. House Speaker Nancy Pelosi, D-Calif., hosted a "meeting of the entire House Democratic caucus in the morning," while Senate Majority Leader Harry Reid plans to hold a news conference that will "build public momentum by framing the issue in more personal terms."

12 Mar 2010

PCMA poll: 74% of people oppose Congress' effort to change FEHBP’s prescription drug benefits

Seventy-four percent of those enrolled in the Federal Health Benefits Program (FEHBP) oppose a new effort by Congress to change the program’s prescription drug benefits, according to a new poll released by the Pharmaceutical Care Management Association.

11 Mar 2010

Passage of legislation could spell disaster for Idaho's health care system

Hundreds of thousands of Idahoans struggling with the high cost of health care received bad news last night -- no relief and more problems are on the way. With the passage of the Idaho Health Freedom Act (House Bill 391), the Senate moved forward legislation that could spell disaster for Idaho's health care system, while addressing none of the health care issues plaguing families across the state.

11 Mar 2010

Idahoans buckling under soaring health care costs: No help from Idaho State Senate

Idahoans buckling under soaring health care costs didn't get any help from the Idaho State Senate tonight. In fact, with the passage of the Idaho Health Freedom Act (House Bill 391), they may have just made matters worse.

10 Mar 2010

FDA's Advisory Committee votes 9-3 to recommend approval of Esbriet for treatment of patients with IPF

InterMune, Inc. announced today that the U.S. Food and Drug Administration's Pulmonary-Allergy Drugs Advisory Committee voted 9-3 to recommend approval of Esbriet® (pirfenidone) for the treatment of patients with idiopathic pulmonary fibrosis (IPF) to reduce decline in lung function.

9 Mar 2010

NASDAQ halts trading of InterMune's common stock, FDA PADAC to discuss pirfenidone NDA

InterMune, Inc. announced that NASDAQ has today halted trading of InterMune's common stock. The Pulmonary-Allergy Drugs Advisory Committee to the U.S. Food and Drug Administration meets today to review and discuss the company's New Drug Application for pirfenidone for the treatment of patients with idiopathic pulmonary fibrosis.

9 Mar 2010

Congress battles over broken health care system; Idaho's homegrown health care crisis may grow even worse

As Congress continues to battle over how to fix the broken health care system, Idaho's homegrown health care crisis may take a giant step towards growing even worse today. The controversial Idaho Health Freedom Act (HB 391) is up for a vote before the full state Senate today. AARP opposes the bill as it could wreak havoc on Idaho's health care system -- resulting in even higher premiums, while costing the state both money and jobs.

9 Mar 2010

State Roundup: N.Y. drug pricing, Vermont hospital ads, Massachusetts nursing homes and anti-psychotics

Poughkeepsie Journal: A new report on New York drug prices, "issued by the New York Public Interest Research Group, Consumers Union, the Center for Medical Consumers and AARP, looked at the price of the 10 most popular drugs found in the state's pharmacies provided through a Freedom of Information Law request. The analysis found a drastic price difference in the same drugs offered in different locations" (Campbell, 3/6).

9 Mar 2010

ISTA Pharmaceuticals' sNDA for once-daily XiDay: FDA assigns PDUFA action date

ISTA Pharmaceuticals, Inc., today announced the Company's supplemental New Drug Application (sNDA) for once-daily XiDay™ (bromfenac ophthalmic solution) has been accepted for review by the U.S. Food and Drug Administration (FDA).

8 Mar 2010

UTSA celebrates grand opening of NVI facility in the greater San Antonio region

The University of Texas at San Antonio celebrates the grand opening of its New Venture Incubator, a facility with laboratory, office and meeting spaces to support technology start-ups in the greater San Antonio region. The incubator, housed on UTSA’s Main Campus, will serve as a bridge between San Antonio entrepreneurs and the region’s research and development community.

8 Mar 2010

Research Roundup: Childhood obesity, insurance coverage in cancer trials, hospitals stays and need for nursing homes

Health Affairs this month is devoted to the topic of childhood obesity, with the first study of the group - National, State, And Local Disparities In Childhood Obesity - pointing out that "new data from the 2007 National Survey of Children's Health show that the percentage of children ages 10-17 who are overweight ... remained stable, while the national prevalence of obesity (BMI in the ninety-fifth percentile and higher) grew significantly, from 14.8 percent in 2003 to 16.4 percent in 2007.

6 Mar 2010

FDA's PADAC meeting to review pirfenidone NDA: InterMune posts briefing documents

InterMune, Inc. announced today that the U.S. Food and Drug Administration (FDA) has posted briefing documents for the March 9 Pulmonary-Allergy Drugs Advisory Committee (PADAC) meeting to review the New Drug Application (NDA) for pirfenidone, InterMune's investigational drug candidate for the treatment of patients with idiopathic pulmonary fibrosis (IPF) to reduce decline in lung function. The proposed trade name for pirfenidone is Esbriet®.

5 Mar 2010

Prescription Drug News and Research

New comprehensive trademark search capabilities available for pharmaceutical industry

Metabolic drugs top the list of prescription drug expenses for elderly Medicare beneficiaries

President delivers emotional speech, pushes for reform in Ohio

BioSante Pharmaceuticals receives receipt of Orphan Drug designation for GVAX Pancreas Vaccine

A.P. Pharma reports net loss of $1.9M for fourth-quarter of 2009

Parliamentarian ruling complicates Democrats' plans

Arena Pharmaceuticals reports lower net loss allocable to common stockholders in fourth-quarter 2009

Does Medicare 'doughnut hole' spur increase in foreign drug imports?

Congress, Obama continue health reform push

PCMA poll: 74% of people oppose Congress' effort to change FEHBP’s prescription drug benefits

Passage of legislation could spell disaster for Idaho's health care system

Idahoans buckling under soaring health care costs: No help from Idaho State Senate

FDA's Advisory Committee votes 9-3 to recommend approval of Esbriet for treatment of patients with IPF

NASDAQ halts trading of InterMune's common stock, FDA PADAC to discuss pirfenidone NDA

Congress battles over broken health care system; Idaho's homegrown health care crisis may grow even worse

State Roundup: N.Y. drug pricing, Vermont hospital ads, Massachusetts nursing homes and anti-psychotics

ISTA Pharmaceuticals' sNDA for once-daily XiDay: FDA assigns PDUFA action date

UTSA celebrates grand opening of NVI facility in the greater San Antonio region

Research Roundup: Childhood obesity, insurance coverage in cancer trials, hospitals stays and need for nursing homes

FDA's PADAC meeting to review pirfenidone NDA: InterMune posts briefing documents

Leveraging the power of automation to boost research

Automating research - solutions and best practices

How can microdialysis benefit drug development

Latest News